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for Sweden [1]. Sensitivity analysis was associated with ICERs ranging up to SEK 
900,000 (c93,856) per QALY gained. CONCLUSIONS: Due to the data limitations, 
HE modeling in the orphan drug setting is challenging. Analysis could be performed 
as requested by Sweden’s Dental and Pharmaceutical Beneﬁ ts Agency (TLV), however, 
providing evidence that health beneﬁ ts can provide good value for money even for an 
orphan population. DLI received a positive reimbursement recommendation by the 
TLV. [1] Persson U, Hjelmgren J (2003).
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OBJECTIVES: To evaluate the cost-effectiveness of rotigotine transdermal patch as 
monotherapy in early-stage Parkinson’s disease (PD) compared to ropinirole and other 
dopamine agonists (DA) from the NHS perspective in Scotland. METHODS: a deci-
sion-analytic model was developed, based on treatment of an early-stage PD patient 
(Hoehn and Yahr-stage 2); treatment arms were rotigotine, ropinirole, and a DA 
practice comparator including ropinirole, cabergoline and pramipexole. 5-year and 
10-year time horizons were considered for patients who remained on monotherapy 
only. The economic evaluation is a cost-utility analysis with health outcomes expressed 
in Quality Adjusted Life-years (QALY) gained in 2006. Costs relating to drug acquisi-
tion, PD severity, falls, occurrence of motor complications and other complications/
adverse events/co-morbidities were considered in the model. Efﬁ cacy and safety data 
were estimated with a meta-analysis. Quality of life was measured using EQ-5D. Data 
on medical resource use was obtained via expert interviews and literature review. 
Costs and effects were discounted at the rate of 3.5%. RESULTS: After 5 years, treat-
ment with rotigotine transdermal patch resulted in an estimated 2.30 QALYs, slightly 
higher than with ropinirole (2.26) and the DA practice comparator (2.27). 10-year 
outcomes were 3.22, 3.17 and 3.17 QALYs for rotigotine, ropinirole and DA practice 
comparator, respectively. Total costs for rotigotine, ropinirole and DA practice com-
parator were £34,748, £37,694 and £36,459 respectively after 5 years and £79,477, 
£84,120 and £81,631, respectively after 10 years. With a willingness-to-pay of 
£20,000 per QALY gained, there is a 90% probability that rotigotine is cost-effective 
relative to ropinirole, and a 85% probability of cost-effectiveness relative to the DA 
practice comparator for both 5-year and 10-year time horizons. CONCLUSIONS: 
Based on the model, rotigotine may be considered a dominant strategy over ropinirole 
and DA practice comparator in the treatment of early-stage PD at 5-year and 10-year 
time horizons.
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OBJECTIVES: In 2005 the Swedish pharmaceutical beneﬁ ts board published a review 
concluding that rizatriptan 10  mg was one of the most cost-effective triptans for 
treating migraine, although efﬁ cacy differences among the triptan class were generally 
small. However, since the review, the price of sumatriptan has declined due to generic 
product entry. In this study, we sought to investigate the cost-effectiveness of rizat-
riptan versus generic sumatriptan. METHODS: A published Canadian decision-ana-
lytic model (Thompson et al., Pharmacoeconomics 2005) was adapted to estimate 
treatment costs and effects of rizatriptan 10 mg versus (generic) sumatriptan in a single 
migraine attack over a 24-hour time-frame in Sweden. Values modiﬁ ed from the 
published model were the substitution of Swedish health care and productivity costs, 
and updated data on 2-hour and 2–24 hour pain freedom (including results from more 
recent head-to-head trials of the comparators). As both sumatriptan 50 mg and 
100 mg are marketed in Sweden, and have comparable efﬁ cacy proﬁ les, averaged data 
for the two doses were used as a comparator to rizatriptan 10 mg. RESULTS: From 
a societal perspective, including both health care and productivity costs, the compari-
son of rizatriptan 10 mg versus (generic) sumatriptan resulted in cost-savings of ~ 5 
SEK, and greater QALYs for rizatriptan 10 mg. Inclusion of health care costs only, 
yielded a cost-effectiveness ratio for rizatriptan vs. sumatriptan of 343,929 SEK/
QALY. CONCLUSIONS: Given the data and assumptions used, in a single attack 
model, rizatriptan 10 mg was found to have a cost-effectiveness ratio compared to 
(generic) sumatriptan within the range typically regarded as cost-effective in Sweden. 
These ﬁ ndings suggest that there is reason to explore the cost-effectiveness of phar-
maceutical and other medical interventions with large differences in acquisition cost 
even though efﬁ cacy differences may appear to be small.
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OBJECTIVES: This study aims at evaluating the incremental cost-effectiveness ratio 
(ICER) for lacosamide compared with standard therapy alone from the perspective of 
the Belgian health care payer in 2010. METHODS: A decision tree simulating the 
treatment pathway of a hypothetical cohort of 1,000 patients over two years was split 
into four phases of six months each during which patients can become seizure free, 
experience a seizure reduction (deﬁ ned as ≥50% reduction in seizures), or withdraw 
due to non-response. The antiepileptic drugs (AEDs) included in the standard therapy 
arm were extracted from the pivotal trials and included carbamazepine, lamotrigine, 
levetiracetam, topiramate and valproate. Health state probabilities, seizure frequency 
and utility values were taken from lacosamide trials or from the literature. Costs of 
general practitioner visits, outpatient visits, hospitalizations and emergency depart-
ment visits were included. Resource use was estimated by a Belgian panel of eight 
neurologists. Costs were discounted at a rate of 3% and consequences at a rate of 
1.5%. RESULTS: Over a 24-month period, standard AED therapy plus lacosamide 
led to a reduction of 7 seizures, an increase of 0.038 quality-adjusted life-years, and 
a cost decrease of c3619 per patient as compared with standard therapy alone. Results 
were also calculated for a 6-, 12- and 18-month follow-up. Lacosamide plus AED 
therapy dominated versus standard therapy alone. Using a willingness to pay of 
c30,000 per quality-adjusted life-year, the net monetary beneﬁ t of standard antiepi-
leptic drug therapy plus lacosamide amounted to c4,754. The probability of standard 
AED therapy plus lacosamide being cost-effective was 97.3% at 6 months, 99.8% at 
12 months, 99.9% at 18 months, and 100% at 24 months. CONCLUSIONS: In 
epileptic patients who are difﬁ cult to treat with other AEDs, standard AED therapy 
plus lacosamide appears to be a cost-effective alternative. 
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OBJECTIVES: Quasi-experimental analysis to determine the effect of an opt-in tele-
phone intervention on adherence in patients using subcutaneous interferon β-1a, 
which is indicated for relapsing-remitting multiple sclerosis. Drop-out reasons, side-
effects, and expectations of therapy are described. METHODS: Customers of a mail-
order pharmacy that services Germany who ordered subcutaneous interferon β-1a 
were targeted for enrollment in a free program that included an initial counseling call, 
optional e-mail reminders for the next doctor’s consultation and prescription, and 
ongoing counseling calls. Patients enrolled in the program for at least 6-months were 
included in the analysis and compared to patients that did not enter the program over 
the same time period. Proportion of days covered (PDC) was calculated for each group 
and compared using analysis of variance. Enrollees in the program were administered 
a questionnaire at the initial welcome call addressing their expectations of therapy, 
and again during each counseling call regarding their compliance behavior, and side 
effects. RESULTS: Patients in the adherence program showed an unadjusted PDC 
8.2% higher than the control, F(1.247) = 13.44, p = 0.0003. One program patient 
switched drugs compared to six control group patients. a total of 21% of enrolled 
subjects reported missing at least one dose. Side-effects included pain/inﬂ ammation at 
the site of injection (24.41%), fatigue (20.73%), headaches (17.06%), and ﬂ u-like 
symptoms (9.71%). Exacerbations were reported by 15.7% of patients. Patients’ had 
expectations that therapy would prolong the distance between exacerbations (23.36%) 
and slow the progression of disability due to the disease (21.28%). CONCLUSIONS: 
Actively recruiting patients into an optional adherence program signiﬁ cantly increased 
the compliance rate for relapsing-remitting multiple sclerosis patients using subcutane-
ous interferon β-1a. Side effects experienced by enrolled patients were consistent with 
the package insert. Limitations include a potential bias between patients that agree to 
the program vs. those that do not, as well as the lack of additional questionnaire data 
from the control group.
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OBJECTIVES: To investigate the possible inﬂ uence of age on the reﬁ ll-based adher-
ence rates of anti-epileptic drugs. METHODS: A retrospective drug utilization review 
was performed on medicine claims data of a pharmacy beneﬁ t management company 
in South Africa. Reﬁ ll-based adherence rates were calculated for 64,457 anti-epileptic 
drugs that were prescribed more than once during a four-year period (January 1, 2005 
to December 2008). The reﬁ ll-based adherence rate was calculated per trade name by 
using the following equation: Reﬁ ll-Adherence rate = (total number of days of anti-
epileptic drugs supplied—days supplied at the last reﬁ ll)/(date last claimed—date ﬁ rst 
claimed). [RSA Rand (R)/$US = 6.38112 (2005); 6.78812 (2006); 7.06926 (2007) and 
8.27505 (2008)]. RESULTS: Only 30.5% (n = 19 635) of anti-epileptic drugs had 
reﬁ ll-adherence rates between between 90% and 110%. The majority of anti-epileptic 
drugs (58.9%; n = 37 962) had reﬁ ll-adherence rates below 90% that accounted for 
39.2% (n = R 57 599 838) of the total cost of all anti-epileptic drugs (N = R146 863 
755) included in these calculations. Anti-epileptic drugs with reﬁ ll-adherence rates 
>110% (10,7%; n = 6 860) accounted for 6.7% (R9 782 864) of the total cost of all 
anti-epileptic drugs. The average reﬁ ll-adherence rate decreased with nearly 10% from 
